Mercks decision to pursue the ZENITH outcomes trial rapidly after STELLAR approval reflected similar competitive awareness: J&Js Opsynvi combination tablet, approved in 2023, had no comparable outcomes data, and securing the hard endpoint label language before any competitor could do so establishes Winrevairs formulary priority on clinical grounds
In SURMOUNT 1, prediabetes reversal to normoglycemia occurred more often in patients on tirzepatide vs
This works similarly to Wegovy it mimics the hormone GLP-1 to help you feel full for longer
Including lean protein sources with carbohydrates at most meals can help control blood sugar levels and combat cravings, so those taking semaglutide can benefit even more from their meal plan
Case reports and small case series have described NAION occurring in patients treated with semaglutide
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), initially approved for the treatment of type 2 diabetes mellitus (T2DM), has emerged as an effective treatment for managing patients with obesity or overweight with at least one weight-related comorbidity ( 2 Methods 2.1 Data source Data on Individual Case Safety Reports (ICSRs) of suspected adverse drug reactions (ADRs) associated with semaglutide were retrieved from the EV database (www.adrreports.eu, accessed on 05 January 2026) and have already been described as a valid system for pharmacovigilance studies ( 2.2 Study population We included only ICSRs involving patients who used a potential counterfeit semaglutide-based product
